Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.64 USD
Change Today +1.61 / 5.36%
Volume 1.2M
RTRX On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

retrophin inc (RTRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/15 - $31.73
52 Week Low
10/1/14 - $7.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RETROPHIN INC (RTRX)

retrophin inc (RTRX) Details

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line includes Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption; Thiola, which is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine; and Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders. The company’s product pipeline also includes compounds for various catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome, and others. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

120 Employees
Last Reported Date: 05/11/15
Founded in 2011

retrophin inc (RTRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $323.2K
Executive Vice President of Research and Deve...
Total Annual Compensation: $430.8K
General Counsel and Secretary
Total Annual Compensation: $95.8K
Compensation as of Fiscal Year 2014.

retrophin inc (RTRX) Key Developments

Retrophin, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Retrophin, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. Non-GAAP operating income for the first quarter 2015 was $1.4 million compared to a non-GAAP operating loss of $17.5 million for the same period in 2014. Net income for the first quarter of 2015 was $39.7 million or $1.32 diluted per share on a GAAP basis compared to a net loss of $75.7 million or $3.25 diluted per share for the same period in 2014. Non-GAAP adjusted net loss for the first quarter of 2015 was $1.1 million or $0.04 per share compared to $17.5 million or $0.75 per share for the same period in 2014. Net product sales were $17,371,800 against $27,900 a year ago. Operating loss was $8,104,443 against $22,061,669 a year ago. Loss before income taxes was $366,162 against $75,670,271 a year ago. Non-GAAP net loss was $1,076,200 or $0.04 diluted per share against $17,527,457 or $0.75 diluted per share a year ago.

Retrophin, Inc. Receives FDA Orphan Drug Designation for RE-024 for the Treatment of Pantothenate Kinase-Associated Neurodegeneration

Retrophin, Inc. announced RE-024, the company’s investigational phosphopantothenate replacement therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pantothenate kinase-associated neurodegeneration (PKAN). PKAN is a rare and lethal autosomal recessive neurodegenerative disorder believed to affect approximately one to three persons per million worldwide, with no approved treatment currently available. Retrophin has initiated the screening of healthy volunteers for its recently announced Phase 1 trial evaluating the safety and tolerability of single oral doses of RE-024. The Orphan Drug Designation program is intended to encourage companies to develop therapeutics for diseases that affect fewer than 200,000 individuals in the United States. Orphan designation will provide RE-024 with seven years of marketing exclusivity if approved by the FDA for the treatment of PKAN. Prior to FDA approval, orphan designation provides incentives for sponsors including tax credits for clinical research expenses, the opportunity to obtain government grant funding to support clinical research, and an exemption from FDA user fees.

Retrophin, Inc. to Propose Amendments to its Certificate of Incorporation and Bylaws

Retrophin, Inc. announced at its annual general meeting to be held on June 8, 2015, will propose amendments to the company's certificate of incorporation and also to approve the amendment and restatement of the company's amended and restated bylaws.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTRX:US $31.64 USD +1.61

RTRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $125.57 USD -1.82
GlaxoSmithKline PLC 1,454 GBp -6.50
Pfizer Inc $34.75 USD +0.31
Shire PLC 5,635 GBp -15.00
View Industry Companies

Industry Analysis


Industry Average

Valuation RTRX Industry Range
Price/Earnings 100.0x
Price/Sales 17.9x
Price/Book 6.2x
Price/Cash Flow 235.8x
TEV/Sales 18.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RETROPHIN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at